Bicocca Open Archive

Logo unimib boa
ALBERTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.188
EU - Europa 6.252
AS - Asia 2.986
OC - Oceania 26
AF - Africa 21
SA - Sud America 21
Continente sconosciuto - Info sul continente non disponibili 15
Totale 21.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.990
IT - Italia 1.515
DE - Germania 1.123
CN - Cina 1.085
SG - Singapore 1.016
IE - Irlanda 877
SE - Svezia 877
RU - Federazione Russa 539
UA - Ucraina 342
HK - Hong Kong 339
GB - Regno Unito 306
CA - Canada 185
VN - Vietnam 129
IN - India 124
FI - Finlandia 123
DK - Danimarca 117
FR - Francia 109
AT - Austria 105
TR - Turchia 92
JP - Giappone 79
KR - Corea 46
BE - Belgio 43
NL - Olanda 39
ES - Italia 36
ID - Indonesia 25
AU - Australia 24
EU - Europa 13
TW - Taiwan 13
CH - Svizzera 12
GR - Grecia 10
PL - Polonia 10
RO - Romania 10
BG - Bulgaria 9
HR - Croazia 9
CZ - Repubblica Ceca 8
IR - Iran 8
EG - Egitto 7
NO - Norvegia 7
AR - Argentina 6
GT - Guatemala 6
SI - Slovenia 6
SC - Seychelles 5
TH - Thailandia 5
ZA - Sudafrica 5
BR - Brasile 4
LU - Lussemburgo 4
MX - Messico 4
MY - Malesia 4
PE - Perù 4
PK - Pakistan 4
SA - Arabia Saudita 4
CL - Cile 3
HU - Ungheria 3
IL - Israele 3
LV - Lettonia 3
RS - Serbia 3
BH - Bahrain 2
CO - Colombia 2
EC - Ecuador 2
IS - Islanda 2
JM - Giamaica 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
BF - Burkina Faso 1
ET - Etiopia 1
GE - Georgia 1
IQ - Iraq 1
KW - Kuwait 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
MM - Myanmar 1
PA - Panama 1
PH - Filippine 1
Totale 21.509
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.158
Fairfield 860
Dublin 851
Singapore 846
Woodbridge 831
Wilmington 790
Chandler 718
Frankfurt am Main 683
Ashburn 549
Milan 540
Houston 529
Dearborn 505
New York 366
Jacksonville 364
Seattle 364
Hong Kong 332
Princeton 330
Cambridge 290
Nanjing 206
Santa Clara 206
Shanghai 139
Boardman 131
Guangzhou 115
Vienna 101
Lawrence 94
Beijing 88
Altamura 75
Dong Ket 69
Lachine 55
Nanchang 55
San Diego 53
Andover 52
Shenyang 50
Chicago 49
Rome 47
Helsinki 46
Toronto 46
Hebei 40
Tianjin 38
Hangzhou 37
Los Angeles 37
Carate Brianza 35
Pune 35
Brussels 33
Jinan 33
Ottawa 33
Mountain View 32
London 31
Tokyo 30
Changsha 29
Norwalk 28
Kunming 27
Falls Church 25
Jakarta 25
Edmonton 24
Melzo 23
Zhengzhou 22
Mainz 21
Shangdi 21
Fremont 20
Jiaxing 19
Dallas 18
Lissone 18
Lappeenranta 17
Washington 17
Sacramento 16
Florence 15
Bologna 14
Ningbo 14
Sesto San Giovanni 14
Yuseong-gu 14
Athens 13
Hefei 12
Kiev 12
Baltimore 11
Brescia 11
Salt Lake City 11
Turin 11
Kocaeli 10
Monza 10
Naples 10
Shenzhen 10
Chengdu 9
Amsterdam 8
Bari 8
Bergamo 8
Cagliari 8
Mumbai 8
Paris 8
Redmond 8
Sydney 8
Canazei 7
Chongqing 7
Codroipo 7
Fort Wayne 7
Granada 7
Hyderabad 7
Munich 7
Perugia 7
Phoenix 7
Totale 15.695
Salva come PNG Salva come JPEG
Nome #
Nelarabine-Induced Neurotoxicity: Reversible Damage not only on Peripheral Nerves 329
Translational Approach to Oxaliplatin Induced Peripheral Neurotoxicity - Neurophysiology: the Link between Bed and Bench "side" 322
Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes 299
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 292
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics 289
Peripheral neuropathy induced by microtubule-targeted chemotherapies: Insights into acute injury and long-term recovery 286
Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings 267
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 246
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 230
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 230
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 227
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 217
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 214
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 212
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 210
Guillain-Barré syndrome related to COVID-19 infection 209
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 202
Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy 200
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 199
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 194
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 191
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data 190
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 187
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 182
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 182
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 181
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 179
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 175
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 174
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 174
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 172
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 172
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 166
Chemotherapy-induced neuropathy 165
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 165
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 165
Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity 165
Severe, reversible nelarabine-induced neuropathy and myelopathy 162
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 161
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 154
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 153
Chemotherapy induced peripheral neurotoxicity: Six essential articles for effective future research 153
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 152
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 151
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 150
ACCURATE NEUROPHYSIOLOGICAL MONITORING FOR SENSORY NEUROPATHY IN MOUSE MODELS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY 149
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 148
Chemotherapy-induced Peripheral Neuropathy 147
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 146
An in vivo and in vitro neurophysiological approach to acute and chronic oxaliplatin-induced peripheral neurotoxicity 145
Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study 145
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale 144
Introduction to the Italian section for young neurologists 144
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 143
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 143
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 142
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 142
Platinum-drugs Induced Peripheral Neurotoxicity: clinical course and preclinical evidence 142
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 140
Neurophysiological examination of dorsal sural nerve 139
Chemotherapy-induced peripheral neurotoxicity–outcome measures: the issue 139
Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? 138
Chemotherapy Induced Peripheral Neurotoxicity (CIPN): neurological burden from a physician and patient point of view 137
Toxic Medications in Charcot-Marie-Tooth Patients: A Systematic Review 135
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 135
When progressive dysphagia could be related to an “old friend” – a case report 134
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 133
Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity 133
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 131
Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study (Int Arch Occup Environ Health, 10.1007/s00420-017-1237-8) 131
Long-term recovery from chemotherapy-induced neuropathy following paclitaxel, ixabepilone, eribulin and vinorelbine in mice 130
Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity 130
EMG Recordings at Rest to Verify Axonal Hyperexcitability in a Rat Model of Oxaliplatin Induced Peripheral Neurotoxicity 130
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 128
Guillain–Barré Syndrome Associated with COVID-19 128
How to assess models of oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 127
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 126
Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy 126
ERIBULIN, PACLITAXEL, IXABEPILONE AND VINORELBINE-INDUCED PERIPHERAL NEUROPATHY IN MICE: INSIGHTS IN LONG-TERM RECOVERY 124
Chemotherapy induced peripheral neurotoxicity: the search for the ideal outcome measure 124
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy 124
Advanced neurophysiology - a translational approach to neuropathy and neuropathic pain 123
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 123
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 122
NERVE EXCITABILITY TESTING IN ANIMAL MODELS OF OXALIPLATIN INDUCED PERIPHERAL NEUROTOXICITY: ION CHANNEL DYSFUNCTION AS A POSSIBLE PATHOGENETIC MECHANISM. 122
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 122
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 121
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 120
The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure 120
Responsiveness and Minimal Clinical Important Difference (MCID) of the Total Neuropathy Score clinical and nurse versions in CIPN 119
Oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 117
Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function 115
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 114
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 114
Pharmacokinetics of IVIg in Wistar rats 112
Toxic neuropathies: chemotherapy induced peripheral neurotoxicity. 111
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 110
Topiramate in Oxaliplatin-Induced Peripheral Neurotoxicity: more than neuroprotection. 110
Neuropatie periferiche 109
Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue 108
Totale 16.209
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.692
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.692
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.234 0 0 235 270 363 528 586 289 336 288 267 72
2020/20213.952 184 153 439 367 290 498 470 505 305 265 172 304
2021/20222.010 147 252 179 179 171 165 79 91 112 130 174 331
2022/20233.550 434 806 333 313 272 575 78 193 251 69 121 105
2023/20243.401 112 168 174 158 389 706 623 161 240 94 95 481
2024/20252.270 449 1.032 789 0 0 0 0 0 0 0 0 0
Totale 23.213